| 查看: 1053 | 回复: 1 | |||
| 当前主题已经存档。 | |||
huajieyu464木虫 (正式写手)
|
[交流]
新的治疗膝关节炎药物
|
||
|
Naproxcinod (formely HCT 3012) Inflammation in osteoarthritis - phase 3 Naproxcinod is NicOx’ lead product, in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. It is a unique nitric oxide-donating anti-inflammatory and the first of the CINOD class (COX-Inhibiting Nitric Oxide Donators). NicOx aims to develop naproxcinod as a powerful anti-inflammatory agent with no detrimental effects on blood pressure and good gastrointestinal tolerability and safety. Top-line results from the first phase 3 study were successful. This represents an important step towards NicOx’ goal of making naproxcinod the drug-of-choice for osteoarthritis patients. |
回复此楼» 猜你喜欢
求助Isoeugenol质量标准
已经有0人回复
-
Gliclazide
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有80人回复
-
塞替派/噻替哌（Thiotepa） 质量控制
已经有16人回复
-
2026考博
已经有0人回复
-
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
-
浙江中医药大学张勇民院士2026年博士研究生招生
已经有3人回复
-
硫醚氧化
已经有2人回复
-
酰胺水解求助
已经有11人回复
-
中药材标准目录大全llp2026（含各省市中药材和炮制规范）
已经有0人回复
-
26博士申请-药物化学方向
已经有24人回复